The response to BCG therapy included strong inhibition of tumor microenvironment genes and immunomodulators including TNFA, IL17, and IL6, suggesting similarities in gene expression profiles between patients undergoing BCG or alpha1‐oleate therapy.39 The gene discussed is IL17A; the disease is neoplasm.